Sartans et risque de cancerBABAI, Samy; BROCVIELLE, Hélène; LEBELLER, Christine et al.Médecine (Montrouge). 2010, Vol 6, Num 9, issn 1777-2044, p. 405Article

High-Affinity Interaction of Sartans with H⁺/Peptide TransportersKNÜTTER, Ilka; KOTTRA, Gabor; FISCHER, Wiebke et al.Drug metabolism and disposition. 2009, Vol 37, Num 1, pp 143-149, issn 0090-9556, 7 p.Article

Association IEC-sartans: que faut-il en penser ? : Hypertension arterielleLa Revue du praticien (Paris). 2010, Vol 60, Num 5, issn 0035-2640, p. 632Article

Sartans: excès de cancers ? = Angiotensin-receptor blocking agent (sartans) and risk of cancersLa Revue Prescrire. 2010, Vol 30, Num 323, issn 0247-7750, p. 672Article

EFFETS INDÉSIRABLES CUTANÉS DES SARTANS = Cutaneous adverse effects of angiotensin II receptor antagonistsLa Revue Prescrire. 2006, Vol 26, Num 276, pp 673-673, issn 0247-7750, 1 p.Article

IEC, sartans ou les deux ?AMBROSI, Pierre.MT. Médecine thérapeutique. 2010, Vol 16, Num 4, pp 374-378, issn 1264-6520, 5 p.Article

Angioödeme durch ACE-Hemmer und AT1-Rezeptor blocker = Angioedema due to ACE inhibitors and AT₁ receptor antagonistsHELLEBRAND, M.-C; KOIDA, G; HOFFMANN, T. K et al.Hautarzt. 2006, Vol 57, Num 9, pp 808-810, issn 0017-8470, 3 p.Article

Antiarythmiques à l'étage atrial : perspectives = Atrial antiarrhythmics : PerspectivesDAVY, J.-M; RACZKA, F; CUNG, T.-T et al.Archives des maladies du coeur et des vaisseaux. 2006, Vol 99, pp 23-29, issn 0003-9683, 7 p., NS5Conference Paper

IEC et sartans : méta-analyse 2007 : Deuxième partie: traitement de l'insuffisance cardiaqueGUEYFFIER, Francois; NOËL-BARON, Florence.Médecine (Montrouge). 2007, Vol 3, Num 8, pp 346-351, issn 1777-2044, 6 p.Article

Prevention of Vascular Injury by Combination of an AT₁ Receptor Blocker, Olmesartan, With Various Calcium AntagonistsINABA, Shinji; IWAI, Masaru; TOMONO, Yumiko et al.American journal of hypertension. 2009, Vol 22, Num 2, pp 145-150, issn 0895-7061, 6 p.Article

Néphropathie diabétique : IEC ou sartans ?LAVILLE, M.La Lettre du cardiologue. 2005, Num 381, pp 35-39, issn 0761-5035, 5 p.Article

The Paleolithic site of ShlenkaASTAKHOV, S. N; ZUBAREVA, G. YU; LISITSYN, N. F et al.Rossijskaâ arheologiâ. 1993, Num 3, pp 140-148, issn 0869-6063Article

A Selective Peroxisome Prol iferator-Activated Receptor-y Modulator, Telmisartan, Binds to the Receptor in a Different Fashion from ThiazolidinedionesTAGAMI, Tetsuya; YAMAMOTO, Hiroyuki; MORIYAMA, Kenji et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 2, pp 862-870, issn 0013-7227, 9 p.Article

Peut-on (quand ?) associer IEC et sartans ?: Canadian Medical Association Journal, 5 avril 2011: prudence chez la personneLE NOC, Yves.Médecine (Montrouge). 2011, Vol 7, Num 6, pp 255-256, issn 1777-2044, 2 p.Article

Non-peptide angiotensin II receptor antagonists: Chemical feature based pharmacophore identificationKROVAT, Eva M; LANGER, Thierry.Journal of medicinal chemistry (Print). 2003, Vol 46, Num 5, pp 716-726, issn 0022-2623, 11 p.Article

Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detectionGONZALEZ, L; LOPEZ, J. A; ALONSO, R. M et al.Journal of chromatography. 2002, Vol 949, Num 1-2, pp 49-60, issn 0021-9673Conference Paper

Optimization of Comorbidity Therapy to Achieve Sustained Viral Response in HCV PatientsUCCIFERRI, Claudio; VECCHIET, Jacopo; PIZZIGALLO, Eligio et al.Hepato-gastroenterology. 2012, Vol 59, Num 117, pp 1589-1590, issn 0172-6390, 2 p.Article

Prospective identification of biologically active structures by topomer shape similarity searchingCRAMER, R. D; POSS, M. A; HERMSMEIER, M. A et al.Journal of medicinal chemistry (Print). 1999, Vol 42, Num 19, pp 3919-3933, issn 0022-2623Article

Olmesartan Attenuates Cardiac Remodeling Through DLL4/Notch1 Pathway Activation in Pressure Overload MiceJIEYUN YOU; JIAN WU; GUOLIANG JIANG et al.Journal of cardiovascular pharmacology. 2013, Vol 61, Num 2, pp 142-151, issn 0160-2446, 10 p.Article

Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary EvidenceVOLPE, Massimo; TOCCI, Giuliano.Drugs & aging. 2013, Vol 30, Num 12, pp 987-998, issn 1170-229X, 12 p.Article

The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric SubjectsSALAZAR, D. E; SONG, S. H; SHI, J et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 2, pp 250-256, issn 0009-9236, 7 p.Article

Predictors of Blood Pressure Response to the Angiotensin Receptor Blocker Candesartan in Essential HypertensionCANZANELLO, Vincent J; BARANCO-PRYOR, Evelyn; RAHBARI-OSKOUI, Frederic et al.American journal of hypertension. 2008, Vol 21, Num 1, pp 61-66, issn 0895-7061, 6 p.Article

Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-γWALCHER, Daniel; HESS, Katharina; MARX, Nikolaus et al.Hypertension (Dallas, Tex. 1979). 2008, Vol 51, Num 2, pp 259-266, issn 0194-911X, 8 p.Article

Iec ou sartan + diurétique + ains : Gare ! = Angiotensin converting enzyme inhibitor or sartan + diuretic + NSAIs : warning !La Revue Prescrire. 2007, Vol 27, Num 279, pp 22-22, issn 0247-7750, 1 p.Article

Olmésartan: entéropathiesLa Revue Prescrire. 2013, Vol 33, Num 362, issn 0247-7750, p. 913Article